| __timestamp | ADMA Biologics, Inc. | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 4241601.57 |
| Thursday, January 1, 2015 | 6745968 | 5392385.38 |
| Friday, January 1, 2016 | 8494742 | 7370036.73 |
| Sunday, January 1, 2017 | 18092835 | 14970357 |
| Monday, January 1, 2018 | 22502922 | 31413266 |
| Tuesday, January 1, 2019 | 25910757 | 72279461 |
| Wednesday, January 1, 2020 | 35050817 | 183907682 |
| Friday, January 1, 2021 | 42896889 | 307644000 |
| Saturday, January 1, 2022 | 52458024 | 472132000 |
| Sunday, January 1, 2023 | 59020000 | 709539000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, argenx SE and ADMA Biologics, Inc. have shown contrasting trends in their SG&A efficiency. From 2014 to 2023, argenx SE's SG&A expenses surged by over 16,000%, reflecting its aggressive expansion and investment in growth. In contrast, ADMA Biologics, Inc. experienced a more modest increase of approximately 1,100%, indicating a steadier approach. By 2023, argenx SE's SG&A expenses were nearly 12 times higher than those of ADMA Biologics, Inc. This divergence highlights the different strategic paths these companies have taken in the biotech landscape. Investors and industry analysts should consider these trends when evaluating the operational efficiency and future potential of these firms.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs ADMA Biologics, Inc.
Selling, General, and Administrative Costs: argenx SE vs Biogen Inc.
Operational Costs Compared: SG&A Analysis of argenx SE and Exelixis, Inc.
Cost Management Insights: SG&A Expenses for argenx SE and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: argenx SE vs Verona Pharma plc
Comparing SG&A Expenses: argenx SE vs Veracyte, Inc. Trends and Insights
Comparing SG&A Expenses: argenx SE vs HUTCHMED (China) Limited Trends and Insights
Cost Management Insights: SG&A Expenses for argenx SE and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of argenx SE and Wave Life Sciences Ltd.
Cost Management Insights: SG&A Expenses for argenx SE and Galapagos NV
ADMA Biologics, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: ADMA Biologics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights